This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parikh, S.
Right arrow Articles by Rosenthal, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parikh, S.
Right arrow Articles by Rosenthal, P. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 2207-2209, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.00022-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin

Sunil Parikh,1* Jun Liu,2 Puran Sijwali,1 Jiri Gut,1 Daniel E. Goldberg,2 and Philip J. Rosenthal1

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California,1 Department of Medicine and Department of Molecular Microbiology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri2

Received 6 January 2006/ Returned for modification 30 January 2006/ Accepted 6 March 2006

Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.

* Corresponding author. Mailing address: University of California San Francisco, Box 0811, San Francisco, CA 94110. Phone: (415) 206-8687. Fax: (415) 648-8425. E-mail: sparikh{at}medsfgh.ucsf.edu.

Antimicrobial Agents and Chemotherapy, June 2006, p. 2207-2209, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.00022-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T. S., Nosten, F., Gardiner, D. L., Boonma, P., Piera, K. A., Andrews, K. T., MacHunter, B., McCarthy, J. S., Anstey, N. M., Price, R. N., Russell, B. (2008). Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrob. Agents Chemother. 52: 2435-2441 [Abstract] [Full Text]  
  • Skinner-Adams, T. S., Andrews, K. T., Melville, L., McCarthy, J., Gardiner, D. L. (2007). Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro. Antimicrob. Agents Chemother. 51: 759-762 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»